Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Applied Therapeutics, Inc. - Common Stock (NQ:APLT)

0.3111 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
APLT ALERT: Kaplan Fox &amp; Kilsheimer LLP Is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 09, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox &amp; Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 07, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
(APLT) - Analyzing Applied Therapeutics's Short Interest
Via Benzinga
Why Applied Therapeutics Stock Is Skyrocketing Today
Investors are cheering good news from the FDA. 
Via The Motley Fool
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - December 06, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
NEW YORK - (NewMediaWire) - December 05, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for resubmission or appeal. 
Via Benzinga
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Third Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Dow Jumps Over 100 Points; Fed Cuts Interest Rates By 0.5%
Via Benzinga
Topics Economy Stocks
Crude Oil Moves Lower; PowerFleet Shares Spike Higher
Via Benzinga
Russell 2000 Outpaces S&P 500 As Small Caps Anticipate Fed's Interest Rate Move
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap counterparts. However, potential for gains may be hindered by sluggish... 
Via Benzinga
Topics Economy Stocks
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug
Applied Therapeutics stock rises as the FDA no longer requires an Advisory Committee meeting, keeping the Priority Review on track, with the PDUFA target date set for November 28. 
Via Benzinga
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Applied Therapeutics to Participate in Upcoming Investor Conferences
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised... 
Via Benzinga
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.